The U.S. Food and Drug Administration on Tuesday announced approval forEli Lilly reported that Kisunla slowed cognitive and functional decline by up to 35% compared to placebo at 18 months in its study.for a similar Alzheimer's drug – lecanemab, also known by its brand name of Leqembi.Maria C. Carrillo, the chief science officer and medical affairs lead for the Alzheimer’s Association, said Wednesday that amyloid plaques are one of the hallmarks of Alzheimer's.
“Decades of this buildup does indeed progressively rob individuals of their ability to think and remember,” she said. “First, it'll block remembering of short-term information and activities that are being conducted. And over time, even automatic functions are impacted, and long-term memory is impacted, unfortunately, ultimately leading to death from Alzheimer's or with Alzheimer's disease.
“Having multiple treatment options like Kisunla, like Leqembi, allow people to have options for treatment that we've been waiting for quite a few decades, so we are very excited,” she said. “But know that this is only our beginning. We need more effective drugs, and we will have not only more effective drugs, but a combination of drugs very soon. So, this is our beginning, and we're very excited about it.
“More time to attend a graduation or a birth of a grandchild, so that is a very impactful, I think, benefit from these drugs in particular,” she said.
Health Health Latest News, Health Health Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: Medscape - 🏆 386. / 55 Read more »
Source: AllSidesNow - 🏆 572. / 51 Read more »
Source: ScienceAlert - 🏆 63. / 68 Read more »
Source: NPR - 🏆 96. / 63 Read more »